Potentiation of the immune system by Schiff base-forming drugs. Mechanism of action and therapeutic potential

BioDrugs

Volumn 7, Issue 3, 1997, Pages 217-231

  Chen, Huaqing ^a   Hall, Simon ^a   Zheng, Biao ^a,b   Rhodes, John ^a  

^a Cell Biology Unit   (United Kingdom)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; BENZALDEHYDE DERIVATIVE; CARBONYL DERIVATIVE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; IMMUNOSTIMULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SCHIFF BASE; T LYMPHOCYTE RECEPTOR; TUCARESOL;

ANIMAL MODEL; ANTIGEN PRESENTING CELL; CHEMISTRY; CHRONIC HEPATITIS; CLINICAL TRIAL; COVALENT BOND; CYTOTOXIC T LYMPHOCYTE; DRUG BIOAVAILABILITY; DRUG MECHANISM; HELPER CELL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPOTENTIATION; MACROMOLECULE; MELANOMA; NONHUMAN; PHYSIOLOGY; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SODIUM TRANSPORT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

EID: 0030747275     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707030-00005     Document Type: Review

References (68)

1. Hendrick SM, Eidelman FJ. T lymphocyte antigen receptors. In: Paul W, editor. Fundamental immunology. 3rd ed. New York: Raven Press, 1993: 383-420
2. Weiss A. T lymphocyte activation. In: Paul W, editor. Fundamental immunology. 3rd ed. New York: Raven Press, 1993: 467-504
3. Lenschow DJ, Bluestone JA. T cell costimulation and in vivo tolerance. Curr Opin Immunol 1993; 5: 747-52
4. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446-514
5. Klima N, Pataraca R, Walling J, et al. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 1994; 8: 1073-81
6. Hendrzak JA, Brunda MJ. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab Invest 1995; 72: 619-37
7. Tahara H, Lotze MT. Anti-tumor effects of interleukin 12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995; 2: 96-106
8. Nabel GJ, Chang AE, Nabel EG, et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994; 5: 57-77
9. Fenton RT, Sznol M, Luster DG, et al. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 1994; 5: 1385-99
10. Rhodes J. Evidence for an intercellular covalent reaction essential in antigen specific T-cell activation. J Immunol 1989; 143: 1482-89
11. Gao X-M, Rhodes J. An essential role for constitutive Schiff base-forming ligands in antigen presentation to murine T cell clones. J Immunol 1990; 144: 2883-90
12. Rhodes J. E-rosettes provide an analogue for Schiff base formation in specific T cell activation. J Immunol 1990; 145: 463-9
13. Rhodes J, Zheng B, Lifely MR. Inhibition of specific T cell activation by monosaccharides is through their reactivity as aldehydes. Immunology 1992; 75: 629-31
14. Zheng B, Brett S, Tite JP, et al. Galactose oxidation in the design of immunogenic vaccines. Science 1992; 256: 1560-3
15. Rhodes J, Chen H, Hall SR, et al. Therapeutic potentiation of the immune system by costimulatory Schiff base forming drugs. Nature 1995; 377: 71-5
16. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995; 81: 979-82
17. Bluestone JA. New perspectives on CD28-B7-mediated T cell costimulation. Immunity 1995; 2: 555-9
18. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994; 6: 414-9
19. Leach DR, Krummel MF, Allison JP. Enhancement of anti-tumour immunity by CTLA-4 blockade. Science 1996; 271: 1734-6
20. Bell GM. Imboden JB. CD2 and the regulation of T cell anergy. J Immunol 1995; 155: 2805-7
21. + T-cells is dependent on B7 (CD80), augmented by CD58, but relatively uninfluenced by CD54 expression. Int Immunol 1995; 7: 1501-13
22. Shevach EM. Accessory molecules. In: Paul W, editor. Fundamental immunology. 3rd ed. New York: Raven Press, 1995: 531-75
23. August A, Dupont B. CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase. Int Immunol 1994; 6: 769-77
24. August AS, Gibson Y, Kawakami T, et al. CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci USA 1994; 91: 9347-50
25. + T-cells. Science 1996; 271: 1272-6
26. + T-cells. Science 1996; 271: 1276-8
27. Vogelzang NJ, Lestingi TM, Sudakoff G, et al. Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum Gene Ther 1994; 5: 1357-70
28. Rubin J, Charboneau JW, Reading C, et al. Phase I study of immunotherapy of hepatic metastases of colorectal cancer by direct gene transfer. Hum Gene Ther 1994; 5: 1371-84
29. Goedegeburne PS, Douville LM, Richmond DC, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995; 13: 1939-49
30. Bauer M, Reaman GH, Hank JA, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkins lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma: a Childrens Cancer Group study. Cancer 1995; 75: 2959-65
31. Heaton KM, Grimm HA. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother 1993; 37: 213-9
32. O'Garra A, Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994 6: 458-66
33. Del-Prete G, Maggi E, Romagnani S. Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. Lab Invest 1994; 70: 299-306
34. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46
35. Gately MK, Gubler U, Brunda MJ, et al. Interleukin 12: acytokine with therapeutic potential in oncology and infectious disease. Ther Immunol 1994; 1: 187-96
36. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15: 575-81
37. Snell EE, Dimari SJ. Schiff base intermediates in enzyme catalysis. In: Boyer PD, editor. The enzymes: kinetics and mechanism. Vol 2. London: Academic Press, 1973: 335-46
38. John RA, Pyridoxal phosphate-dependent enzymes. Biochim Biophys Acta 1995; 1248: 81-96
39. Fersht A. Covalent catalysis. In: Enzyme structure and mechanism. 2nd ed. New York: W.H. Freeman, 1984: 69-97
40. Van der Meer RA, Duine JA. Covalently bound pyrroloquinoline quinone is the organic prosthetic group of human placental lysyl oxidase. Biochem J 1986; 239: 789-91
41. Stryer L. Excitable membranes and sensory systems. In: Biochemistry. 3rd ed. New York: W.H. Freeman, 1988: 1005-41
42. Mukohata Y. Comparative studies on ion pumps of the bacterial rhodopsin family. Biophys Chem 1994; 50: 191-201
43. Sasaki J, Brown, LS, Chon Y-S, et al. Conversion of bacterior-hodopsin into a chloride ion pump. Science 1995; 269: 73-5
44. Rolan PE, Parker JE, Gray SJ, et al. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4-[2-formyl-3-hydroxyphenoxymethyl]benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. Br J Pharmacol 1993; 35: 419-25
45. Seger R, Krebs EG. The MAPK signalling cascade. FASEB J 1995; 9: 726-35
46. Dudley DT, Pang L, Decker SJ, et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-9
47. Greenlaw R, Robinson P, Heaton T, et al. Transfection of HLA-DR-expressing DAP.3 cells with a cDNA clone encoding the glycosyl phosphatidylinositol-linked form of lymphocyte function associated antigen-3: biochemical features and functional consequences. Int Immunol 1992; 4: 673-80
48. Wyss DF, Choi JS, Maria JL, et al. Conformation and function of the N-linked glycan in the adhesion domain of human CD2. Science 1995; 269: 1273-8
49. Malkovsky M, Edwards AJ, Hunt R, et al. T-cell mediated enhancement of host-versus-graft reactivity in mice fed a diet enriched with vitamin A acetate. Nature 1983; 302: 338-40
50. Malkovsky M, Medawar PB, Thatcher DR. et al. Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci USA 1985; 82: 536-8
51. Buck J, Derguini F, Levi E, et al. Intracellular signalling by 14-hydroxy-4, 14-retro-retinol. Science 1991; 254: 1645-56
52. Derguini F, Nakanishi K, Hämmerling U, et al. Intracellular signaling activity of synthetic (14R)-, (14S)-, and (14RS)-14-hydroxy-4, 14-retro-retinol. Biochemistry 1994; 33: 623-8
53. Meydani SN, Ribaya-Mercado JD, Russell RM, et al. Vitamin B6 deficiency impairs interleukin 2 production and lymphocyte proliferation in elderly adults. Am J Clin Nutr 1991; 53: 1275-80
54. Rall C, Meydani SN, Vitamin B6 and immune competence. Nutr Rev 1993; 51: 217-25
55. Deeg HJ. Ultraviolet irradiation in transplant biology: manipulation of immunity and imunogenicity. Transplantation 1988; 45: 845-51
56. Ullrich SE, Modulation of immunity by ultraviolet radiation: key effects on antigen presentation. J Invest Dermatol 1995; 105 (1 Suppl.): 30-6S
57. Kripke ML. Ultraviolet radiation and immunology: something new under the sun [presidential address]. Cancer Res 1994; 54: 6102-5
58. Soltysik S, Wu JY, Recchia J, et al. Structure/function analysis of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995; 13: 1403-10
59. 2 immune responses. Proc Natl Acad Sci USA 1995; 92: 10128-32
60. Tzianobos AO, Onderdonk AB, Rosner B, et al. Structural features of polysaccharides that induce intra-abdominal abscesses. Science 1993; 262: 416-9
61. Tzianobos AO, Onderdonk AB, Smith RS, et al. Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect Immun 1994; 62: 3590-3
62. Sherman DI, Williams R. Liver damage: mechanisms and management. Br Med Bull 1994; 50: 124-38
63. Edmonds SE, Ellis G, Gaffney K, et al. Hypoxia and the rheumatoid joint: immunological and therapeutic implications. Scand J Rheumatol Suppl 1995; 101: 163-8
64. Love RA, Rader JI, Crofford LJ, et al. Pathological and immunological effects of ingesting L-tryptophan and 1,1′-ethylidenebis-(L-tryptophan) in Lewis rats. J Clin Invest 1993; 91: 804-11
65. Dreskell WJ, Ashley DL, Grainger J, et al. Identification of decomposition products of 1,1′-ethylidenebis-(L-tryplophan), a compound associated with eosinophilia-myalgia syndrome. Bull Environ Contam Toxicol 1992; 48: 679-87
66. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995; 49: 105-9
67. Redfield RR, Birx DL. HIV-specific vaccine therapy: concepts, status, and future directions. AIDS Res Hum Retrovir 1992; 8: 1051-8
68. Barth A, Hoon DS, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54: 3342-5